Search research articles
Contact Us
Filters
Showing results (1-10 of 57) with videos related to
Page
of 6
Sort By:
Anti-Cancer Drugs
|
April 20, 2004
Re: 'Radiation recall dermatitis induced by pegylated liposomal doxorubicin'
Franco M Muggia
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2016
Intraperitoneal Therapy for Ovarian Cancer
Franco M Muggia
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2002
Boosting bioavailability to topotecan: what do we gain?
Franco M Muggia
Clinical Advances in Hematology & Oncology : H&O
|
September 9, 2020
The Benefits of Reducing My Hours to Half-Time (That Is, Three-Quarter Time)
Franco M Muggia
The New England Journal of Medicine
|
June 11, 2005
Phase 1 clinical trials in oncology
Franco M Muggia
Seminars in Oncology
|
February 24, 2005
Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers
Franco M Muggia
The Oncologist
|
February 21, 2002
Thoughts about September 11, 2001: civilization's resilience and tenacity
Franco M Muggia
Seminars in Oncology
|
February 24, 2005
Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer
Franco M Muggia
Molecular Cancer Therapeutics
|
April 23, 2009
Heidelberger symposium on the 50th anniversary of fluoropyrimidines
Franco M Muggia
Anti-Cancer Drugs
|
April 8, 2014
Introduction: why a supplement on taxanes?
Franco M Muggia
Page
of 6
Search research articles
Search
Showing results (1-10 of 57) with videos related to
Sort By:
Page
of 6
Anti-Cancer Drugs
|
April 20, 2004
Re: 'Radiation recall dermatitis induced by pegylated liposomal doxorubicin'
Franco M Muggia
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2016
Intraperitoneal Therapy for Ovarian Cancer
Franco M Muggia
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2002
Boosting bioavailability to topotecan: what do we gain?
Franco M Muggia
Clinical Advances in Hematology & Oncology : H&O
|
September 9, 2020
The Benefits of Reducing My Hours to Half-Time (That Is, Three-Quarter Time)
Franco M Muggia
The New England Journal of Medicine
|
June 11, 2005
Phase 1 clinical trials in oncology
Franco M Muggia
Seminars in Oncology
|
February 24, 2005
Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers
Franco M Muggia
The Oncologist
|
February 21, 2002
Thoughts about September 11, 2001: civilization's resilience and tenacity
Franco M Muggia
Seminars in Oncology
|
February 24, 2005
Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer
Franco M Muggia
Molecular Cancer Therapeutics
|
April 23, 2009
Heidelberger symposium on the 50th anniversary of fluoropyrimidines
Franco M Muggia
Anti-Cancer Drugs
|
April 8, 2014
Introduction: why a supplement on taxanes?
Franco M Muggia
Page
of 6